Pathophysiology of cardiotoxicity from target therapy and angiogenesis inhibitors

Journal of Cardiovascular Medicine

Volumn 17, Issue , 2016, Pages S19-S26

  Maurea, Nicola ^a   Coppola, Carmela ^a   Piscopo, Giovanna ^a   Galletta, Francesca ^a   Riccio, Gennaro ^b   Esposito, Emanuela ^a   De Lorenzo, Claudia ^b,c   De Laurentiis, Michelino ^a   Spallarossa, Paolo ^d   Mercuro, Giuseppe ^e  

^a NATIONAL CANCER INSTITUTE   (Italy)

^b CEINGE BIOTECNOLOGIE AVANZATE   (Italy)

^c UNIVERSITY OF NAPLES FEDERICO II   (Italy)

^d UNIVERSITY OF GENOA   (Italy)

^e UNIVERSITY OF CAGLIARI   (Italy)

Author keywords

cancer therapy; cardiotoxicity; ErbB2; trastuzumab; vascular endothelial growth factor inhibitors

Indexed keywords

ANGIOGENESIS INHIBITOR; AXITINIB; DASATINIB; EPIDERMAL GROWTH FACTOR RECEPTOR 2; IMATINIB; LAPATINIB; MONOCLONAL ANTIBODY; NILOTINIB; PERTUZUMAB; PONATINIB; PROTEASOME INHIBITOR; REGORAFENIB; SORAFENIB; SUNITINIB; TRASTUZUMAB; TRASTUZUMAB EMTANSINE; VANDETANIB; VASCULOTROPIN INHIBITOR; VASCULOTROPIN; ANTINEOPLASTIC AGENT; VASCULOTROPIN A;

ARTICLE; CARDIOTOXICITY; CARDIOVASCULAR RISK; DRUG EFFECT; DRUG SAFETY; HUMAN; MOLECULARLY TARGETED THERAPY; PATHOPHYSIOLOGY; SIGNAL TRANSDUCTION; ANTAGONISTS AND INHIBITORS; CARDIOVASCULAR DISEASE; CHEMICALLY INDUCED; DRUG EFFECTS; HEART; NEOPLASM; ANIMAL; BREAST NEOPLASMS; FEMALE; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; MOUSE;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; CARDIOTOXICITY; CARDIOVASCULAR DISEASES; HEART; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEASOME INHIBITORS; RECEPTOR, ERBB-2; VASCULAR ENDOTHELIAL GROWTH FACTORS; ANIMALS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; FEMALE; HEART FAILURE; MICE; SIGNAL TRANSDUCTION; TRASTUZUMAB; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84970016562     PISSN: 15582027     EISSN: 15582035     Source Type: Journal    
DOI: 10.2459/JCM.0000000000000377     Document Type: Article

References (66)

1. Blaes AH, Gaillard P, Peterson BA, et al. Angiotensin converting enzyme inhibitors may be protective against cardiac complications following anthracycline chemotherapy. Breast Cancer Res Treat 2010; 122: 585-590
2. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science 1987; 235: 177-182
3. Chien KR. Myocyte survival pathways and cardiomyopathy: implications for trastuzumab cardiotoxicity. Semin Oncol 2000; 27: 9-14
4. Crone SA, Zhao YY, Fan L, et al. ErbB2 is essential in the prevention of dilated cardiomyopathy. Nat Med 2002; 8: 459-465
5. Force T, Krause DS, Van Etten RA. Molecular mechanisms of cardiotoxicity of tyrosine kinase inhibition. Nat Rev Cancer 2007; 7: 332-344
6. Stebbing J, Copson E, O?Reilly S. Herceptin (trastuzamab) in advanced breast cancer. Cancer Treat Rev 2000; 26: 287-290
7. Seidman A, Hudis C, Pierri MK, et al. Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002; 20: 1215-1221
8. De Keulenaer GW, Doggen K, Lemmens K. The vulnerability of the heart as a pluricellular paracrine organ: lessons from unexpected triggers of heart failure in targeted ErbB2 anticancer therapy. Circ Res 2010; 106: 35-46
9. Fedele C, Riccio G, Malara AE, et al. Mechanisms of cardiotoxicity associated with ErbB2 inhibitors. Breast Cancer Res Treat 2012; 134: 595-602
10. Keefe DL. Trastuzumab-Associated cardiotoxicity. Cancer 2002; 95: 1592-1600
11. Perez EA, Rodeheffer R. Clinical cardiac tolerability of trastuzumab. J Clin Oncol 2004; 22: 322-329
12. Fiú za M. Cardiotoxicity associated with trastuzumab treatment of HER2? breast cancer. Adv Ther 2009; 26(Suppl 1): S9-S17
13. Ewer MS, Lippman SM. Type II chemotherapy-related cardiac dysfunction: time to recognize a new entity. J Clin Oncol 2005; 23: 2900-2902
14. Bowles EJA, Wellman R, Feigelson HS, et al. Risk of heart failure in breast cancer patients after anthracicline and trastuzumab treatment: a retrospective cohort study. J Natl Cancer Inst 2012; 104: 1293-1305
15. Kokubo H, Miyagawa-Tomita S, Tomimatsu H, et al. Targeted disruption of hesr2 results in atrioventricular valve anomalies that lead to heart dysfunction. Circ Res 2004; 95: 540-547
16. Gude N, Sussman M. Notch signaling and cardiac repair. J Mol Cell Cardiol 2012; 52: 1226-1232
17. Dogan I, Cumaoglu A, Aricioglu A, Ekmekci A. Inhibition of ErbB2 by herceptin reduces viability and survival, induces apoptosis and oxidative stress in Calu-3 cell line. Mol Cell Biochem 2011; 347: 41-51
18. Elzarrad MK, Mukhopadhyay P, Mohan N, et al. Trastuzumab alters the expression of genes essential for cardiac function and induces ultrastructural changes of cardiomyocytes in mice. PLoS One 2013; 8: e79543
19. Tocchetti CG, Carpi A, Coppola C, et al. Ranolazine protects from doxorubicin-induced oxidative stress and cardiac dysfunction. Eur J Heart Fail 2014; 16: 358-366
20. Xiong Y, Liu X, Lee CP, et al. Attenuation of doxorubicin-induced contractile and mitochondrial dysfunction in mouse heart by cellular glutathione peroxidase. Free Radic Biol Med 2006; 41: 46-55
21. Forrest GL, Gonzalez B, Tseng W, et al. Human carbonyl reductase overexpression in the heart advances the development of doxorubicin-induced cardiotoxicity in transgenic mice. Cancer Res 2000; 60: 5158-5164
22. Ewer MS, Ewer SM. Troponin I provides insight into cardiotoxicity and the anthracycline-trastuzumab interaction. J ClinOncol 2010; 28: 3901-3904
23. Rayson D, Richel D, Chia S, et al. Anthracycline-trastuzumab regimens for HER2/neu-overexpressing breast cancer: current experience and future strategies. Ann Oncol 2008; 19: 1530-1539
24. Toko H, Oka T, Zou Y, et al. Angiotensin II type 1a receptor mediates doxorubicin-induced cardiomyopathy. Hypertens Res 2002; 25: 597-603
25. Zeglinski M, Ludke A, Jassal DS, Singal PK. Trastuzumab-induced cardiac dysfunction: a ?dual-hit?. Exp Clin Cardiol 2011; 16: 70-74
26. Onitilo AA, Engel JM, Stankowski RV, et al. High-sensitivity C-reactive protein (hs-CRP) as a biomarker for trastuzumab-induced cardiotoxicityin HER2-positive early-stage breast cancer: a pilot study. Breast Cancer Res Treat 2012; 134: 291-298
27. Russell SD, Blackwell KL, Lawrence J, et al. Independent adjudication of symptomatic heart failure with the use of doxorubicin and cyclophosphamide followed by trastuzumab adjuvant therapy: a combined review of cardiac data from the National Surgical Adjuvant breast and Bowel Project B-31 and the North Central Cancer Treatment Group N9831 clinical trials. J Clin Oncol 2010; 28: 3416-3421
28. Smith I, Procter M, Gelber RD, et al. 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial. Lancet 2007; 369: 29-36
29. Ewer SM, Ewer MS. Cardiotoxicity profile of trastuzumab. Drug Saf 2008; 31: 459-467
30. Balduzzi S, Mantarro S, Guarneri V, et al. Trastuzumab-containing regimens formetastatic breast cancer. Cochrane Database Syst Rev 2014; 12: CD006242
31. Dhillon S. Trastuzumab emtansine: a review of its use in patients with HER2-positive advanced breast cancer previously treated with trastuzumab-based therapy. Drugs 2014; 74: 675-686
32. Krop IE, Suter TM, Dang CT, et al. Feasibility and cardiac safety of trastuzumab emtansine after anthracycline-based chemotherapy as (neo)adjuvant therapy for human epidermal growth factor receptor 2-positive early-stage breast cancer. J Clin Oncol 2015; 33: 1136-1142
33. Bhave M, Akhter N, Rosen ST. Cardiovascular toxicity of biologic agents for cancer therapy. Oncology (Williston Park) 2014; 28: 482-490
34. Baselga J, Cortes J, Kim SB, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012; 366: 109-119
35. Girardi F, Franceschi E, Brandes AA. Cardiovascular safety of VEGFtargeting therapies: current evidence and handling strategies. Oncologist 2010; 15: 683-694
36. Perez EA, Koehler M, Byrne J, et al. Cardiac safety of lapatinib: pooled analysis of 3689 patients enrolled in clinical trials. Mayo Clin Proc 2008; 83: 679-686
37. Azim H, Azim HA Jr, Escudier B. Trastuzumab versus lapatinib: the cardiac side of the story. Cancer Treat Rev 2009; 35: 633-638
38. Borst DL, Arruda LS, MacLean E, et al. Common questions regarding clinical use of axitinib in advanced renal cell carcinoma. Am J Health Syst Pharm 2014; 71: 1092-1096
39. Hamnvik OP, Larsen PR, Marqusee E. Thyroid dysfunction from antineoplastic agents. J Natl Cancer Inst 2011; 103: 1572-1587
40. Pithavala YK, Chen Y, Toh M, et al. Evaluation of the effect of food on the pharmacokinetics of axitinib in healthy volunteers. Cancer Chemother Pharmacol 2012; 70: 103-112
41. Rini BI, Escudier B, Tomczak P, et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (axis): a randomised phase 3 trial. Lancet 2011; 378: 1931-1939
42. Gressett SM, Shah SR. Intricacies of bevacizumab-induced toxicities and their management. Ann Pharmacother 2009; 43: 490-501
43. Hawkes EA, Okines AF, Plummer C, Cunningham D. Cardiotoxicity in patients treated with bevacizumab is potentially reversible. J Clin Oncol 2011; 29: e560-e562
44. Khawaja MZ, Cafferkey C, Rajani R, et al. Cardiac complications and manifestations of chemotherapy for cancer. Heart 2014; 100: 1133-1140
45. Chu TF, Rupnick MA, Kerkela R, et al. Cardiotoxicity associated with tyrosine kinase inhibitor sunitinib. Lancet 2007; 370: 2011-2019
46. Escudier B, Eisen T, Stadler WM, et al. Sorafenib in advanced clear-cell renal-cell carcinoma. N Engl J Med 2007; 356: 125-134
47. Motzer RJ, Hutson TE, Tomczak P, et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007; 356: 115-124
48. Hutson TE, Figlin RA, Kuhn JG, Motzer RJ. Targeted therapies for metastatic renal cell carcinoma: an overview of toxicity and dosing strategies. Oncologist 2008; 13: 1084-1096
49. Veronese ML, Mosenkis A, Flaherty KT, et al. Mechanisms of hypertension associated with BAY 43-9006. J Clin Oncol 2006; 24: 1363-1369
50. Chintalgattu V, Ai D, Langley R, et al. Cardiomyocyte PDGFR-beta signaling is an essential component of the mouse cardiac response to loadinduced stress. J Clin Invest 2010; 120: 472-484
51. Hasinoff BB, Patel D, O?Hara KA. Mechanisms of myocyte cytotoxicity induced by the multiple receptor tyrosine kinase inhibitor sunitinib. Mol Pharmacol 2008; 74: 1722-1728
52. Kerkela R, Woulfe KC, Durand JB, et al. Sunitinib-induced cardiotoxicity is mediated by off-target inhibition of AMP-Activated protein kinase. Clin Transl Sci 2009; 2: 15-25
53. US Food and Drug Administration (FDA)-Approved manufacturer?s package insert available online at http://dailymed.nlm.nih.gov/ailymed/lookup.cfm?setid?807f988e-117b-4497-934d-73aa78baac71 [Accessed 3 January1 2013]
54. D?Alessandro R, Refolo MG, Lippolis C, et al. Antagonism of sorafenib and regorafenib actions by platelet factors in hepatocellular carcinoma cell lines. BMC Cancer 2014; 14: 351
55. Wilhelm SM, Dumas J, Adnane L. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011; 129: 245-255
56. Ghatalia P, Je Y, Kaymakcalan MD, et al. QTc interval prolongation with vascular endothelial growth factor receptor tyrosine kinase inhibitors. Br J Cancer 2015; 112: 296-305
57. Bronte G, Bronte E, Novo G, et al. Conquests and perspectives of cardiooncology in the field of tumor angiogenesis-targeting tyrosine kinase inhibitor-based therapy. Expert Opin Drug Saf 2015; 14: 253-267
58. Hennequin LF, Stokes ES, Thomas AP, et al. Novel 4-Anilinoquinazolines with C-7 basic side chains: design and structure activity relationship of a series of potent, orally active, VEGF receptor tyrosine kinase inhibitors. J Med Chem 2002; 45: 1300-1312
59. Carlomagno F, Vitagliano D, Guida T, et al. ZD6474, an orally available inhibitor of KDR tyrosine kinase activity, efficiently blocks oncogenic RET kinases. Cancer Res 2002; 62: 7284-7290
60. Haverkamp W, Breithardt G, Camm AJ, et al. The potential for QT prolongation and pro-Arrhythmia by nonanti-Arrhythmic drugs: Clinical and regulatory implications. Report on a Policy Conference of the European Society of Cardiology. Cardiovasc Res 2000; 47: 219-233
61. Senkus E, Jassem J. Cardiovascular effects of systemic cancer treatment. Cancer Treat Rev 2011; 37: 300-311
62. http://www.accessdata.fda.gov/drugsatfda-docs/label/2012/202714lbl.pdf?et-cid?29661884&et-rid?463638624&linkid?http%3a%2f%2fwww.accessdata.fda.gov%2fdrugsatfda-docs%2f label%2f2012%2f202714lbl.pdf. [Accessed 13 August 2012]
63. Richardson PG, Sonneveld P, Schuster MW, et al. Bortezomib or highdose dexamethasone for relapsed multiple myeloma. N Engl J Med 2005; 352: 2487
64. Grandin EW, Ky B, Cornell RF, et al. Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. J Card Fail 2015; 21: 138
65. Truong J, Yan AT, Cramarossa G, Chan KK. Chemotherapy-induced cardiotoxicity: detection, prevention, and management. Can J Cardiol 2014; 30: 869-878
66. Madonna R, Cadeddu C, Deidda M, et al. Improving the preclinical models for the study of chemotherapy-induced cardiotoxicity: a Position Paper of the Italian Working Group on Drug Cardiotoxicity and Cardioprotection. Heart Fail Rev 2015; 20: 9497-9504